The company, infamous and long derided in the genetic testing community for refusing to share BRCA1/2 variants, has decided to change its stance as part of a "strategic transformation."
Patent Board Rules Broad Institute First With Functioning CRISPR System in Eukaryotic Cells
The ruling is the latest decision in the fight between the Broad and the University of California for control over the bulk of the IP rights to CRISPR-Cas9.
The company's CRISPR-chrom technology fuses chromatin-modulating peptides to CRISPR nucleases, essentially moving chromatin out of the way for more efficient editing.
European Patent Office Upholds UC Berkeley CRISPR Patent
The EPO rejected arguments that were filed in opposition to the patent, which covers the use of CRISPR-Cas9 in cellular and non-cellular settings.
Revocation of Broad Institute CRISPR Patent Upheld in Europe
The European Patent Office appeals board upheld the decision made by the EPO after its initial review in 2018.